199 related articles for article (PubMed ID: 28732324)
41. Usefulness of the Ultrasensitive Anti-Müllerian Hormone Assay for Predicting True Ovarian Reserve.
Iwase A; Osuka S; Nakamura T; Kato N; Takikawa S; Goto M; Kikkawa F
Reprod Sci; 2016 Jun; 23(6):756-60. PubMed ID: 26614267
[TBL] [Abstract][Full Text] [Related]
42. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.
Yu B; Douglas N; Ferin MJ; Nakhuda GS; Crew K; Lobo RA; Hershman DL
Cancer; 2010 May; 116(9):2099-105. PubMed ID: 20187091
[TBL] [Abstract][Full Text] [Related]
43. Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study.
Evranos B; Faki S; Polat SB; Bestepe N; Ersoy R; Cakir B
Thyroid; 2018 Dec; 28(12):1702-1707. PubMed ID: 30156472
[No Abstract] [Full Text] [Related]
44. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.
Yeo W; Mo FKF; Pang E; Suen JJS; Koh J; Loong HHF; Yip CCH; Ng RYW; Yip CHW; Tang NLS; Liem GS
BMC Womens Health; 2017 Jul; 17(1):55. PubMed ID: 28750616
[TBL] [Abstract][Full Text] [Related]
45. Association between spontaneous ovulation and serum anti-Müllerian hormone levels in a premature ovarian insufficiency patient after a multimodal treatment for breast cancer.
Wakimoto Y; Fukui A; Wakimoto G; Ikezawa Y; Matsuoka M; Omote M; Sugiyama Y; Ukita Y; Kato T; Shibahara H
J Obstet Gynaecol Res; 2019 Nov; 45(11):2297-2301. PubMed ID: 31456293
[TBL] [Abstract][Full Text] [Related]
46. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
[TBL] [Abstract][Full Text] [Related]
47. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
[TBL] [Abstract][Full Text] [Related]
48. Impact of Taxanes, Endocrine Therapy, and Deleterious Germline
Lambertini M; Olympios N; Lequesne J; Calbrix C; Fontanilles M; Loeb A; Leheurteur M; Demeestere I; Di Fiore F; Perdrix A; Clatot F
Front Oncol; 2019; 9():575. PubMed ID: 31355134
[No Abstract] [Full Text] [Related]
49. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
50. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments.
Silva C; Ribeiro Rama AC; Reis Soares S; Moura-Ramos M; Almeida-Santos T
J Ovarian Res; 2019 Oct; 12(1):102. PubMed ID: 31672154
[TBL] [Abstract][Full Text] [Related]
51. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation.
Liebenthron J; Reinsberg J; van der Ven K; Saenger N; Kruessel JS; von Wolff M
Hum Reprod; 2019 Dec; 34(12):2513-2522. PubMed ID: 31782794
[TBL] [Abstract][Full Text] [Related]
52. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Iwamoto T; Hara F; Uemura Y; Mukai H; Watanabe T; Ohashi Y
Breast Cancer Res Treat; 2020 Jul; 182(2):325-332. PubMed ID: 32462261
[TBL] [Abstract][Full Text] [Related]
53. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
[TBL] [Abstract][Full Text] [Related]
54. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
55. Anti-Mullerian-hormone levels during pregnancy and postpartum.
Köninger A; Kauth A; Schmidt B; Schmidt M; Yerlikaya G; Kasimir-Bauer S; Kimmig R; Birdir C
Reprod Biol Endocrinol; 2013 Jul; 11():60. PubMed ID: 23844593
[TBL] [Abstract][Full Text] [Related]
56. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels.
Henes M; Froeschlin J; Taran FA; Brucker S; Rall KK; Xenitidis T; Igney-Oertel A; Lawrenz B; Henes JC
Rheumatology (Oxford); 2015 Sep; 54(9):1709-12. PubMed ID: 25957439
[TBL] [Abstract][Full Text] [Related]
57. [An experiment control study on the ovarian reserve function after cisplatin intraperitoneal or intravenous chemotherapy in rats model].
Fan BZ; Xia H; Chu L; Tong XW
Zhonghua Fu Chan Ke Za Zhi; 2017 Apr; 52(4):249-253. PubMed ID: 28441841
[No Abstract] [Full Text] [Related]
58. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
[TBL] [Abstract][Full Text] [Related]
59. Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide.
D'Avila ÂM; Biolchi V; Capp E; Corleta Hv
J Ovarian Res; 2015 Dec; 8():82. PubMed ID: 26667243
[TBL] [Abstract][Full Text] [Related]
60. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
